Synthetic Lethality and DNA Damage
Alan D. D’Andrea, M.D.
Chair of IDEAYA SAB | Professor, Harvard Medical School and Member, National Academy of Medicine
Alan D’Andrea, M.D. is the Fuller-American Cancer Society Professor of Medicine at Harvard Medical School and the Director of the Center for DNA Damage and Repair at the Dana-Farber Cancer Institute in Boston. His research is focused on the identification of genetic vulnerabilities in human cancers including leukemia, ovarian, and breast cancer. Dr. D’Andrea is a member of the Board of Scientific Counselors of the National Cancer Institute and is a recipient of the G.H.A. Clowes Award from the American Association of Cancer Research. He currently co-leads the Stand up to Cancer Ovarian Cancer Dream Team with Dr. Elizabeth Swisher.
Trey Ideker, Ph.D.
Professor, University California at San Diego
Trey Ideker, Ph.D., is a Professor in Medicine, Bioengineering and Computer Science at UCSD; Co-Director of the Cancer Genomes and Networks Program at UCSD Moores Comprehensive Cancer Center, and Director of the San Diego Center for Systems Biology. His lab develops technology to build molecular network maps of the cell and to use these networks to translate genotype to phenotype in cancer. He has founded influential bioinformatic tools including Cytoscape, a popular network analysis platform which has been cited >12,000 times. Ideker serves on the Editorial Boards for Cell, Cell Reports, Molecular Systems Biology, and PLoS Computational Biology and is a Fellow of AAAS and AIMBE. He was named one of the Top 10 Innovators of 2006 by Technology Review magazine and was the recipient of the 2009 Overton Prize from the International Society for Computational Biology.
Stephen Kowalczykowski, Ph.D.
Professor, University of California at Davis, and Member, National Academy of Sciences
Stephen Kowalczykowski, Ph.D., is a Distinguished Professor of Microbiology and Molecular Genetics, and of Molecular and Cell Biology at the University of California at Davis. He received his Ph.D. in chemistry and biochemistry with Dr. Jacinto Steinhardt at Georgetown University. His postdoctoral training was with Dr. Peter von Hippel at the University of Oregon. Dr. Kowalczykowski started his independent faculty career in 1981 at Northwestern University Medical School. In 1991, he relocated to the University of California at Davis with the rank of Full Professor. He subsequently served as the Chair of Microbiology and the Director of the Center for Genetics and Development. Dr. Kowalczykowski’s honors include election to the National Academy of Sciences (2007), the American Academy of Arts and Sciences (2005), the American Academy of Microbiology (2003), and the American Association for the Advancement of Science (2001). Dr. Kowalczykowski’s research programs focus on the molecular mechanisms of recombinational DNA repair; the function of homologous recombination in the maintenance of genomic integrity.
John Petrini, Ph.D.
Member, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
John Petrini, Ph.D., is a Member in the Molecular Biology Program of the Sloan Kettering Institute at the Memorial Sloan Kettering Cancer Center in New York, and the founding Director of the Functional Genomics Initiative at MSKCC. Dr. Petrini received his Ph.D. in 1988 from the University of Michigan Medical School, Ann Arbor, MI, and conducted postdoctoral work at the Dana Farber Cancer Institute at the Harvard Medical School. He began his independent research career at the University of Wisconsin in 1994, and was recruited to MSKCC in 2002. The work in Dr. Petrini’s lab is focused on the DNA damage response, a network of functions comprising DNA damage signaling, DNA repair, and DNA damage dependent cell cycle regulation. His laboratory employs yeast and mice to undertake genetic, molecular biological, and biochemical analyses of the pathways in eukaryotic cells that are responsive to chromosome breaks.
Elizabeth Swisher, M.D.
Professor, University of Washington
Elizabeth Swisher, M.D., is a gynecologic oncologist, Professor of Gynecologic Oncology, and adjunct Professor of Medical Genetics at the University of Washington in Seattle. Dr. Swisher’s research focused on understanding the role of the BRCA-Fanconi anemia pathway in ovarian cancer and how defects in DNA repair can be exploited in the therapy and prevention of ovarian carcinoma. She is co-Leader of Stand up to Cancer’s first Ovarian Cancer Dream Team. She is principal investigator on several PARP inhibitor therapeutic trials and collaborates on the translational research for numerous other clinical trials in ovarian and other cancers.
Lawrence Fong, M.D.
Co-Leader, Cancer Immunotherapy Program, and Efim Guzik Distinguished Professor in Cancer Biology at UCSF
Dr. Lawrence Fong is Co-Leader, Cancer Immunotherapy Program, and Efim Guzik Distinguished Professor in Cancer Biology at the Helen Diller Cancer Center at UCSF. Dr. Fong’s laboratory is focused on how the immune system interacts with cancer, investigating how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity in patients. Dr. Fong is also co-director and medical director of the Parker Institute of Cancer Immunotherapy (PICI) at UCSF. He has served on National Cancer Institute (NCI) Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)-Immunotherapy Task Force, and is a senior editor for Cancer Immunology Research. Dr. Fong is also the site principal investigator at UCSF for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN). Dr. Fong received his B.A. degree from Columbia University and his M.D. degree from Stanford University, and completed an oncology fellowship at Stanford before joining the medical staff there in 1999. He joined UCSF in 2002.
Paul J. Reider, Ph.D.
Faculty, Princeton University
Paul J. Reider, Ph.D., joined the faculty of Princeton University in 2008 where his research is focused on new drugs for malaria, TB and other neglected diseases. During his 28 years in the pharmaceutical industry he has directly contributed to the discovery, identification, development or registration of 14 approved drugs. From 2002-2007 he was at Amgen as Worldwide Head of Chemistry Research & Discovery. He received his A.B. (Psychology) at New York University and his Ph.D. (Organic Chemistry) at the University of Vermont. After post-doctoral research as an NIH National Research Service Awardee at Colorado State University, Paul joined Merck as a Senior Research Chemist in Process Chemistry where he remained for 22 years. Prior to joining Amgen, he was Vice President of Process Chemistry at Merck. Paul is the winner of numerous awards, most recently, he was named the winner of the 2011 National Academy of Sciences’ Award for Chemistry in Service to Society. He has served on the visiting committees for Harvard University, California Institute of Technology, and the University of California, Santa Barbara, and on the Editorial Advisory Boards of the Journal of the American Chemical Society, the Journal of Organic Chemistry, and Organic Letters. He is also a Senior Editor of Current Opinion in Drug Discovery & Development, and Science of Synthesis. In 2011, Paul joined the Scientific Advisory Boards of the Medicines for Malaria Venture and the TB Alliance.
Laura Shawver, Ph.D.
President and CEO, Synthorx
Laura Shawver, Ph.D. is president, chief executive officer, and director of Synthorx. Prior to joining Synthorx, Dr. Shawver held the following positions: CEO and director of Cleave Biosciences, entrepreneur-in-residence for 5AM Ventures, CEO and director of Phenomix Corporation, and president of SUGEN Inc. (acquired by Pharmacia). Shawver has been involved with a number of clinical development programs including two FDA-approved therapies. Shawver is currently a director of Relay Therapeutics as well as an advisor to the industry. She is an active member of the American Association for Cancer Research serving on the Scientific Advisory Committee for Stand Up to Cancer. Shawver knows firsthand what it is like to be a cancer patient. Having survived ovarian cancer, she turned that experience into the founding of The Clearity Foundation, a nonprofit organization providing access to molecular profiling for ovarian cancer patients to improve their treatment options. Shawver received her Ph.D. in pharmacology and a B.S. degree in microbiology both from the University of Iowa.
William R. Sellers, M.D.
Core Institute Member, Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School
Dr. Sellers is a Core Institute Member at the Broad Institute and faculty member of the Dana-Farber Cancer Institute and Harvard Medical School. From 2005-2016, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for BioMedical Research, during which the oncology research group brought more than 30 cancer therapeutics into first-in-man trials including therapeutics targeting the PI3K, CDK4, IDH, ABL, SMO, HER3, ALK, Wnt, PIM and Ras pathways among others. Along with Dr. Carl June, he co-chaired the CART collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval.
Prior to Novartis, Dr. Sellers was an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute where he initiated large-scale projects which led to discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma. In addition, his work advanced the understanding of the molecular mechanisms of growth regulation of the PTEN tumor suppressor gene. Dr. Sellers was a member of the National Cancer Advisory Board from 2011 to 2016. Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed residency training in Internal Medicine at the University of California San Francisco in 1989 and trained in Medical Oncology at the Dana-Farber Cancer Institute.